BRISTOL-MYERS SQUIBB CO (BMY) Stock News

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

This Unpopular Dividend Stock Is a Buy

Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

2 High-Yield Dividend Stocks to Buy Early in 2025

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol Myers Squibb Stock Earns 83 RS Rating

On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program

/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers...

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Tuesday Sector Leaders: Healthcare, Consumer Products